Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1993-12-06
1997-03-04
Bond, Robert T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540488, A01N 4300, A61K 3155, C07D28116
Patent
active
056079290
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to the use of certain dibenzothiazepinones as antiviral agents.
A group of dibenzothiazepinone derivatives has now been found which show activity as antiviral agents. Thus, according to one aspect, the present invention provides the use of compounds of formula (I) ##STR2## wherein: n is 0, 1 or 2; and or more ring substituent(s) selected from: cycloalkyl or C.sub.1-6 alkoxy (where the alkyl or cycloalkyl moiety may be optionally substituted by one or more substituents selected from halogen atoms and hydroxyl groups); different, each represent hydrogen or C.sub.1-6 alkyl; hydrogen, C.sub.1-6 alkyl or C.sub.3-6 cycloalkyl; above; group may be optionally substituted by one or more substituents independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, nitro, halogen and amino; and cycloalkyl;
According to one embodiment, the invention provides the use of compounds of formula (I) as defined above in which R.sup.3 represents hydrogen for the manufacture of a medicament for the treatment of a virus disease.
As used herein the term "alkyl" as a group or part of a group means a straight or branched chain alkyl group. Such alkyl groups preferably have 1 to 3 carbon atoms and are more preferably methyl or ethyl, most preferably methyl.
The present invention also provides compounds of formula (I) wherein: or R.sup.1 is hydrogen; and substituent(s) selected from: selected from halogen atoms and hydroxyl groups, or C.sub.1-6 alkoxy substituted by one or more substituents selected from halogen atoms and hydroxyl groups; different, each represent hydrogen or C.sub.1-6 alkyl; hydrogen, C.sub.1-6 alkyl or C.sub.3-6 cycloalkyl; or different, each represent C.sub.1-6 alkyl or one of R.sup.4 and R.sup.5 represents C.sub.1-6 alkyl and the other represents hydrogen; group may be optionally substituted by one or more substituents independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, nitro, halogen and amino; and substituents selected from halogen atoms and hydroxyl groups, or C.sub.1-6 alkoxy substituted by one or more substituents selected from halogen atoms and hydroxyl groups; different, each represent C.sub.1-6 alkyl or one of R.sup.4 and R.sup.5 represents C.sub.1-6 alkyl and the other represents hydrogen; hydrogen, C.sub.1-6 alkyl or C.sub.3-6 cycloalkyl; C.sub.1-6 alkyl or one of R.sup.4 and R.sup.5 represents C.sub.1-6 alkyl and the other represents hydrogen; group may be optionally substituted by one or more substituents independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, nitro, halogen and amino; and from: cycloalkyl or C.sub.1-6 alkoxy (where the alkyl or cycloalkyl moiety may be optionally substituted by one or more substituents selected from halogen atoms and hydroxyl groups); different, each represent hydrogen or C.sub.1-6 alkyl; hydrogen, C.sub.1-6 alkyl or C.sub.3-6 cycloalkyl; above; group may be optionally substituted by one or more substituents independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, nitro, halogen and amino; and cycloalkyl; and that R.sup.2 does not represent methyl when R.sup.1 represents methoxy; or or more ring substituent(s) selected from: cycloalkyl or C.sub.1-6 alkoxy (where the alkyl or cycloalkyl moiety may be optionally substituted by one or more substituents selected from halogen atoms and hydroxyl groups); different, each represent hydrogen or C.sub.1-6 alkyl; hydrogen, C.sub.1-6 alkyl or C.sub.3-6 cycloalkyl; above; group may be optionally substituted by one or more substituents independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, nitro, halogen and amino; and cycloalkyl; or more ring substituent(s) selected from: cycloalkyl or C.sub.1-6 alkoxy (where the alkyl or cycloalkyl moiety may be optionally substituted by one or more substituents selected from halogen atoms and hydroxyl groups); different, each represent hydrogen or C.sub.1-6 alkyl; hydrogen, C.sub.1-6 alkyl or C.sub.3-6 cycloalkyl; above; group may be optionally substituted by one or more substituents indepe
REFERENCES:
patent: 3367930 (1968-02-01), Schmuts et al.
patent: 3541085 (1970-11-01), Sheeley et al.
patent: 3853882 (1974-12-01), Szmuskovicz
patent: 3887575 (1975-06-01), Hester, Jr. et al.
patent: 4002639 (1977-01-01), Vogt
patent: 4163785 (1979-08-01), Hoffmann et al.
patent: 4263207 (1981-04-01), Rokach et al.
patent: 4728735 (1988-03-01), Belanger et al.
R. Pauwls, Nature, vol. 343, pp. 470-473, "Potent and Selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivative," (1990).
N. Rasanu, Rev. Chim, vol. 20(3), pp. 175-176, "Chimia tioxantonei. Transpozitia Beckman a oximei tioxantonei si oximei tioxanton-5,5-dioxidului," 1969.
A. H. Corwin, A. B. Chivvis, and C. B. Storm, Chemical Abstract, vol. 62, pp. 14681-14684, "Seven- and Higher-Membered Rings," (1965).
J. Schmutz, F. Kunzle, F. Hunziker and A. Burki, Helvetica Chimica Acta, vol. 48, No. 38, pp. 336-347, "Neue Synthese von Lactamen der Dibenz[v,f]-1, 4-thiazepin-, -oxazepin und Dibenz[b,e]-azepin-Reihe," (1965).
P. Catsoulacos, Bulletin de la Societe Chimique de France, No. 6, pp. 2136-2137, "Synthese de derives du dibenzo[b, f] thiazein-1,4 one-10 dioxyde-5,5," (1973).
D. Besanty, J. Mayrargue, G. E. Moussa, M. E. Shaaban, P. Gayral, M. Miocque, Eur. J. Med. Chem, vol. 23, pp. 403-405, "Synthese de benzo et dibenzothiazepines nitrees a visee anti-parasitaire," (1988).
D. Hellwinkel, R. Lenz and F. Lammerzahl, Tetrahedron, vol. 39, No. 12, pp. 2073-2084, "Heterocyclic Syntheses via Carbanionically Induced Rearrangement Reactoins" (1983).
N. Kamigata, S. Hashimoto, M. Kobayashi and H. Nakanishi, The Chemical Society of Japan, No. 58, pp. 3131-3136, "Photochemical Ring-expansion Reaction of 1,2-Benzisothiazolinones," (1985).
Z. Polivka, J. Holubek, E. Svatek, A. Dlabac, D. Pucek, Z. Z. Sedivy and M. Protiva, Collection Czechoslovak Chem Commun., vol. 48, pp. 1465-1476, "3-(4-Methyliperazino)Dibenzo[b,f]-1,2,4-Triazolo[4,3-d]-1,4-Thiazepine and its 6-Chloro and 12-Chloro Derivatives"; Synthesis and Pharmacology, (1983).
J. Joshi, B. C. Joshi and F. S. K. Barar, Pharmazie, No. 44, pp. 265-267, "Synthesis and Pharmacological evaluation of triazolo derivatives of 8-amino-10, 11-dihydro-dibenzo[b,e]1,4-thiazepin-11-one," (1989).
O. F. Bennett, J. Johnson and J. Tramondozzi, Organic Preparations and Procedures, Int., 6(6), pp. 287-293, "Synthesis of 2-Methoxydibenzo [b,f] (1,4)-Thiazepin-11 (10H) -One-5, 5-Dioxide," (1974).
N. Kamigata, S. Hashimoto and M. Kobayashi, Sulfur Letters, vol. 2(1), pp. 17-22, "On Direct Photo-Oxidation of Benzisothiazol-3 (2H)-Ones in the Presence of Oxygen," (1984).
G. P. Dhareshwar and B. D. Hosangadi, Indian J. Chem, vol. 15B, pp. 963-964, "Studies in Amination & Intramolecular Amidation Reactions with Polyphosphoric Acid: Synthesis of 2-Aminodiphenyl Sulphone, Dibenzo [b,f][1,4]thiazepin-11(10H)-one-5,5-dioxide & Dibenz[b,f][1,4]oxazepin-11(10H)-one," (1977).
N. Kamigata, S. Hashimoto, S. Fujie, and M. Kobayashi, J. Chem. Soc., Chem. Commun., pp. 765-766, "Photoisomerization of 2-Aryl-1,2-benzisothiazol-3(2H)-ones," (1983).
O. F. Bennett, J. Johnson and S. Galletto, Journal of Heterocyclic Chemistry, vol. 12, pp. 1211-1213, "A Novel Synthesis of Dibenzo [b,f][1,4]thiazepin-11(10H)one 5,5-Dioxides," (1975).
B. C. Joshi and J. Pande, Chemistry and Industry, pp. 825-826, "Synthesis and structural studies of 9-amino-10,11-dihydro-5H-dibenzo(b,e)(1,4)thiazepine 11-one," (1985).
K. Nagarajan, C. L. Kulkarni, A. Venkateswarlu and R. K. Shah, Indian Journal of Chemistry, vol. 12, pp. 258-262, "Condensed Heterotricycles: Dibenz [b,f][1,4]oxazepines-11(10H)-thiones, 11-Substituted Dibenze[b,f][1,4]oxazepines & Dibenz[b,f][1,4]thiazepin Analogues," (1974).
K. Nagarajan, C. L. Kulkarni, and A. Venkateswarlu, Indian Journal of Chemistry, vol. 12, pp. 247-251, "Condensed Heterotricycles: Beckmann Rearrangement of Xanthone & Thioxanthone Oximes as a Route to Dibenz[b,f][1,4]-oxazepines & Thiazepines," (1974).
K. Nagarajan, A. Venkateswarlu, C. L. Kulkarny a
Hodgson Simon T.
Nicol Robin H.
Slater Martin J.
Bond Robert T.
Glaxo Wellcome Inc.
LandOfFree
Antiviral dibenzothiazepinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiviral dibenzothiazepinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral dibenzothiazepinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2146066